Pneumococcal Vaccine Market Growth Analysis, Outlook Report 2024-2033

Overview and Scope

The pneumococcal vaccine refers to a vaccination that offers defense against potentially fatal and severe pneumococcal infections caused by streptococcus pneumoniae bacteria, such as pneumonia, meningitis, and sepsis. It is highly efficient in protecting infants from one of the most common causes of meningitis and other illnesses, such as acute ear infections.

Sizing and Forecast

The pneumococcal vaccine market size has grown strongly in recent years. It will grow from $8.47 billion in 2023 to $9.04 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%.  The  growth in the historic period can be attributed to discovery of streptococcus pneumoniae, public health concern, early vaccination efforts, healthcare advancements, vaccine policy changes.

The pneumococcal vaccine market size is expected to see strong growth in the next few years. It will grow to $11.36 billion in 2028 at a compound annual growth rate (CAGR) of 5.9%.  The growth in the forecast period can be attributed to evolving pneumococcal strains, continued research and development, immunization priorities, expanded vaccine access, population aging. Major trends in the forecast period include multivalent vaccine development, vaccination in at-risk group, boosting vaccine efficacy, education and awareness campaigns, targeting infant immunization.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/pneumococcal-vaccine-global-market-report

Segmentation & Regional Insights

The pneumococcal vaccine market covered in this report is segmented –

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products

2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous

3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels

4) By End User: Pediatrics, Adults

North America  was the largest region in the pneumococcal vaccine market in 2023. Asia-Pacific  is expected to be the fastest-growing region in the forecast period. The regions covered in the pneumococcal vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East,  Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11950&type=smp

Major Driver Impacting Market Growth

The increasing prevalence of pneumococcal contamination is expected to propel the growth of the pneumococcal vaccine market going forward. Pneumococcal contamination refers to any infection caused by bacteria called Streptococcus pneumoniae or pneumococcus, such as pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine stimulates the body to produce antibodies against pneumococcal bacteria to reduce or destroy disease-carrying bacteria and toxins to protect children, the elderly, and those with weakened immune systems from many types of pneumococcal infections. For instance, in January 2022, according to the Center for Disease Control and Prevention, a US-based agency for public health, Pneumococcal pneumonia causes an estimated 150,000 hospitalizations per year in the United States, accounting for up to 30% of adult community-acquired pneumonia. Therefore, the increasing prevalence of pneumococcal contamination is driving the growth of the pneumococcal vaccine market.

Key Industry Players

Major companies operating in the pneumococcal vaccine market report are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Novartis International AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Astellas Pharma Inc., CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Emergent BioSolutions Inc., Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Valneva SE, Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, Inventprise LLC, Tergene Biotech Private Limited, PnuVax Incorporated, SK Bioscience Co Ltd

The pneumococcal vaccine market report table of contents includes:

1. Executive Summary
2. Pneumococcal Vaccine Market Characteristics
3. Pneumococcal Vaccine Market Trends And Strategies
4. Pneumococcal Vaccine Market – Macro Economic Scenario
5. Global Pneumococcal Vaccine Market Size and Growth

.

.

.

32. Global Pneumococcal Vaccine Market Competitive Benchmarking
33. Global Pneumococcal Vaccine Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Pneumococcal Vaccine Market
35. Pneumococcal Vaccine Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

 

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model